Description of the medicine: Molgramostim (Molgramostim)
MOLGROMOSTIM (Molgramostim) *.
Synonyms: Leikomaks, Leucomax [name of the drug company "Sandoz" (Switzerland)].
Molgramostim has a certain immunotropic activity; it stimulates the growth of T-lymphocytes (but not B-lymphocytes). The main specific property of mogramostim is its ability to stimulate leukopoiesis, therefore it is used as an anti-leukopenic agent.
Until recently, there were not enough effective specific anti-leukopenic drugs. To a certain extent, drugs leukogen, methylthiouracil, pentoxyl, butyrol stimulate leukopoiesis (see). To stimulate leukopoiesis, immunostimulating drugs thymalin, sodium nucleinate, etc. are also used.
The recent establishment of milgramostim has been an important contribution to the treatment of leukopenia. This preparation is a recombinant (obtained by genetic engineering) human granulocyte macrophage colony stimulating factor. Thus, molgramostim is an endogenous factor involved in the regulation of hematopoiesis and the functional activity of leukocytes. It stimulates the proliferation and differentiation of blood cell precursors, as well as the growth of granulocytes, monocytes; increases the content of mature cells in the blood.
The drug leycomax (molgramostim) is a highly purified water-soluble protein consisting of 127 amino acid residues. Leukomax is used for the treatment and prevention of leukopenia in pathological conditions accompanied by impaired myeloid hematopoiesis. The drug accelerates the recovery of myeloid hematopoiesis; helps prevent potential infectious complications of leukopenia.
Doses and the scheme of administration of the drug depend on the indications and the course of the pathological process.
In case of aplastic (hypoplastic) anemia, 3 mcg / kg (0.003 mc / kg) is administered under the skin once a day. The therapeutic effect usually occurs after 2 to 4 days, after which the dose is selected individually so as to maintain the white blood cell count at the desired level, usually not higher than 10 * 10 9 / L.
In case of leukopenia that has arisen during chemotherapy of tumors, 5–10 mcg / kg is administered once a day under the skin. The drug begins to be administered 1 day after the completion of the chemotherapy cycle. Along with chemotherapy, leukomax is not used. Leukomax is administered at the indicated doses for 7 to 10 days.
The chemotherapy cycle is repeated 48 hours after the cessation of leukomax administration.
Leukomax is also used in the treatment of AIDS patients. With monotherapy, 1 mcg / kg is administered under the skin once a day; when combined with specific antiviral drugs (see Ganciclovir) - 1 to 3 - 5 mcg / kg per day. The effect is usually observed on the 2nd - 4th day. Then the dose is selected individually (every 3 to 5 days) in order to maintain the white blood cell count at the desired level, usually not higher than 10 * 10 9 / L.
For bone marrow transplantation, 5 to 10 μg / kg of leukomax is administered per day.